Target Name: IL1RN
NCBI ID: G3557
Review Report on IL1RN Target / Biomarker Content of Review Report on IL1RN Target / Biomarker
IL1RN
Other Name(s): ICIL-1RA | IL1RN (IL1F3) | INN=Anakinra | Interleukin 1 receptor antagonist, transcript variant X1 | IL1RN variant 2 | Interleukin-1 receptor antagonist protein (isoform 1) | IL-1ra | interleukin 1 receptor antagonist | MVCD4 | type II interleukin-1 receptor antagonist | intracellular IL-1 receptor antagonist type II | IL1RN variant 1 | IRAP | Interleukin 1 receptor antagonist, transcript variant 3 | Anakinra | Interleukin 1 receptor antagonist, transcript variant 4 | MGC10430 | IL-1ra3 | IL-1 inh | IL1 inhibitor | IL1 INH | Type II interleukin-1 receptor antagonist | IL1RN variant 3 | IL1RA | Intracellular IL-1 receptor antagonist type II | Interleukin-1 receptor antagonist protein | Interleukin-1 receptor antagonist protein (isoform 4) | IL1F3 | IL-1-inh | Interleukin 1 receptor antagonist, transcript variant 1 | intracellular interleukin-1 receptor antagonist (icIL-1ra) | Interleukin-1 receptor antagonist protein (isoform 3) | IL-1RN | IL1RN variant X1 | Interleukin 1 receptor antagonist, transcript variant 2 | DIRA | Interleukin-1 receptor antagonist protein (isoform 2) | IL1RA_HUMAN | Intracellular interleukin-1 receptor antagonist (icIL-1ra) | IL-1RA | OTTHUMP00000203730 | IL1RN variant 4

Potential Drug Target for IL1RN in Autoimmune Diseases and as A Biomarker for Immune Function

IL1RN (Interleukin-1 receptor antagonist-like protein-2) is a protein that is expressed in various tissues throughout the body, including the immune system, pancreas, and brain. It is a member of the IL1R family, which is known for its role in the regulation of inflammation and immune responses.

IL1RN has been identified as a potential drug target due to its involvement in the immune response and its ability to modulate the activity of immune cells. The IL1R family has been shown to play a role in the regulation of inflammation and immune cell function, and IL1RN has been shown to interact with several key transcription factors and cytokines.

One of the most promising aspects of IL1RN is its potential as a therapeutic agent for the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. These conditions involve an overactive immune response that can cause damage to the body's tissues, and IL1RN has been shown to have a negative impact on the immune response in individuals with these conditions.

In addition to its potential as a therapeutic agent, IL1RN has also been identified as a potential biomarker for the monitoring of immune function. The activity of IL1RN has been shown to be affected by a variety of factors, including inflammation, stress, and exercise, and changes in these factors have been associated with changes in the expression of IL1RN.

Furthermore, IL1RN has also been shown to play a role in the regulation of pancreatic function, which is important for maintaining the health and function of the pancreas. Individuals with pancreatitis, a common complication of pancreatic surgery, have been shown to have decreased levels of IL1RN, which may contribute to the development and progression of pancreatitis.

Overall, IL1RN is a protein that has the potential to be a drug target or a biomarker for a variety of conditions. Further research is needed to fully understand the role of IL1RN in the immune and pancreatic systems, and to determine its potential as a therapeutic agent.

Protein Name: Interleukin 1 Receptor Antagonist

Functions: Anti-inflammatory antagonist of interleukin-1 family of proinflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens

The "IL1RN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1RN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA | INCA1 | INCENP | INE1 | INE2 | INF2 | ING1 | ING2 | ING2-DT | ING3 | ING4 | ING5